GLP-1 (S) Research Overview: GLP-1 Receptor Agonism (2026)

<p>GLP-1 (S) is a synthetic GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA under multiple brand names (Ozempic, Wegovy, Rybelsus) for type 2 diabetes and obesity. As a research compound, GLP-1 (S)'s well-characterized pharmacology — particularly its mechanism at the GLP-1 receptor — makes it one of the most studied reference compounds in incretin biology and metabolic pathway research.</p><h2>Molecular Profile</h2><p>MW: 4113.58 g/mol | CAS: 910463-68-2 | Classification: GLP-1 receptor agonist, acylated GLP-1 analog | Sequence: 31-amino acid GLP-1 analog with C18 fatty acid side chain for albumin binding</p><h2>GLP-1 Receptor Mechanism</h2><p>GLP-1 (S) binds the GLP-1 receptor (GLP-1R), a class B GPCR expressed in pancreatic beta cells, the central nervous system, gastrointestinal tract, cardiovascular tissue, and kidney. GLP-1R activation by GLP-1 (S) triggers Gs-mediated cAMP accumulation, stimulating glucose-dependent insulin secretion and inhibiting glucagon release. In the CNS, GLP-1R activation in hypothalamic and brainstem circuits has been studied for effects on appetite-regulating pathway signaling.</p><h2>Comparison with Earlier GLP-1 Agonists</h2><p>GLP-1 (S)'s structural advantage over earlier GLP-1 agonists (exenatide, liraglutide) is its C18 fatty diacid modification enabling strong albumin binding — extending the half-life to approximately 7 days in humans. This sustained receptor engagement has made GLP-1 (S) a useful tool for studying prolonged GLP-1R activation effects in research models.</p><p>↗ Lau J et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue GLP-1 (S). J Med Chem. PubMed ID: 25726804</p><h2>Research Applications</h2><ul><li>GLP-1 receptor binding affinity and selectivity studies</li><li>Incretin pathway and insulin secretion research</li><li>Central nervous system satiety circuit research</li><li>Comparative pharmacology vs. TZ2 – GLP2 and RT3 – GLP3</li><li>Cardiovascular biology pathway research</li></ul><h2>Frequently Asked Questions</h2><p>Q: Is research-grade GLP-1 (S) the same as Ozempic?</p><p>A: No. Research-grade GLP-1 (S) is for in-vitro laboratory research only. It is not a pharmaceutical product and not interchangeable with FDA-approved prescription medications.</p><p>Q: What makes GLP-1 (S)'s mechanism different from TZ2 – GLP2?</p><p>A: GLP-1 (S) is a single GLP-1R agonist. TZ2 – GLP2 is a dual GLP-1R and GIPR agonist. The addition of GIP receptor engagement in TZ2 – GLP2 represents a mechanistically distinct approach studied for additive metabolic effects.</p><p>Related: TZ2 – GLP2 Research Guide → | RT3 – GLP3 Research Guide → | Cagrilintide Research Guide → | GLP-1 Overview →</p>